Search
Carboplatin Treatment Options in Canada
A collection of 336 research studies where Carboplatin is the interventional treatment. These studies are located in the Canada . Carboplatin is used for conditions such as Non-Small Cell Lung Cancer, Ovarian Cancer and Lung Cancer.
157 - 168 of 336
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
Active Not Recruiting
The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating participants with previously untreated inoperable or metastatic urothelial cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Local Institution - 0001, Anchorage, Alaska +173 locations
Conditions: Urothelial Cancer
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
Active Not Recruiting
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: Alaska Oncology and Hematology, LLC., Anchorage, Alaska +100 locations
Conditions: Non-small Cell Lung Cancer
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
Active Not Recruiting
The primary aim of this randomized phase III trial was to study whether the addition of maintenance chemotherapy delivered after surgical resection and focal radiation would be better than surgery and focal radiation alone. The trial also studied if patients who received induction chemotherapy and then either achieved a complete response or went on to have a complete resection would also benefit from maintenance chemotherapy. Children ages 1-21 years with newly diagnosed intracranial ependymoma... Read More
Gender:
ALL
Ages:
Between 12 months and 21 years
Trial Updated:
10/16/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama +208 locations
Conditions: Anaplastic Ependymoma, Brain Ependymoma, Cellular Ependymoma, Clear Cell Ependymoma, Ependymoma, Papillary Ependymoma
Phase III Study of AK112 for NSCLC Patients
Active Not Recruiting
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: CBCC Global Research, Bakersfield, California +73 locations
Conditions: Non-Squamous Non-small Cell Lung Cancer
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Active Not Recruiting
This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California +43 locations
Conditions: Extensive Stage Small Cell Lung Cancer
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
Active Not Recruiting
This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work in treating young patients with newly diagnosed supratentorial primitive neuroectodermal tumors or high-risk medulloblastoma when given before additional intense chemotherapy followed by peripheral blood stem cell rescue. It is not yet known which combination chemotherapy regimen is more effective when given before a peripheral stem cell transplant in treating supratentorial... Read More
Gender:
ALL
Ages:
2 years and below
Trial Updated:
09/16/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama +144 locations
Conditions: Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor, Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified
Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma
Completed
The best treatment for resectable esophageal or gastroesophageal adenocarcinoma is unknown. Although an operation to remove the esophagus is the most common treatment, previous studies have shown that patients live longer when either perioperative (before and after surgery) chemotherapy or preoperative (before surgery) chemotherapy plus radiation is given, compared to surgery alone. However it is unknown which of these treatments (perioperative chemotherapy or preoperative chemoradiation) is mor... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/26/2024
Locations: Health Sciences Centre / CancerCare Manitoba, Winnipeg, Manitoba +2 locations
Conditions: Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction
SGI-110 in Combination With Carboplatin in Ovarian Cancer
Completed
A 2-part, Phase 2 controlled, open-label, randomized study in participants with platinum-resistant recurrent ovarian cancer. In Part 1, participants received SGI-110 and carboplatin. The optimum dose of SGI-110 (guadecitabine) was identified in Part 1 based on safety and efficacy. In Part 2, participants were randomized to receive the dose identified in Part 1 plus carboplatin or one of four treatment of choice at the discretion of the investigator. The treatment of choice consisted of topotecan... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/31/2024
Locations: Norris Comprehensive Cancer Center- University of Southern California, Los Angeles, California +23 locations
Conditions: Ovarian Cancer
Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)
Completed
Participants with Stage IV nonsquamous non-small cell lung cancer (NSCLC) without prior systemic treatment will be treated with standard of care pembrolizumab combined with platinum-doublet chemotherapy for 4 cycles, then pembrolizumab plus pemetrexed maintenance for up to 31 additional cycles. The platinum doublet would be pemetrexed plus the investigator's choice of either cisplatin or carboplatin. The primary objective is to evaluate if total baseline tumor mutation burden (TMB) in cell-free... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2024
Locations: University Of Colorado ( Site 0908), Aurora, Colorado +14 locations
Conditions: Non-Small Cell Lung Cancer
Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol
Completed
To determine if treatment with cisplatin and radiation followed by carbo and taxol reduces the rate of recurrence when compared to sandwich therapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/22/2024
Locations: Greater Baltimore Medical Center, Baltimore, Maryland +6 locations
Conditions: Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer
Using ctDNA to Determine Therapies for Lung Cancer
Recruiting
This is a study to look at whether the presence of circulating tumour DNA (ctDNA) in the blood can help to predict whether giving adjuvant treatment after surgery can decrease the chance of the cancer coming back in people with lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2024
Locations: Princess Margaret Cancer Centre, Toronto, Ontario
Conditions: Non Small Cell Lung Cancer, Complete Surgical Resection, Circulating Tumor DNA
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
Active Not Recruiting
The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed participants with extensive-stage small cell lung cancer (ES-SCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2024
Locations: Local Institution - 0075, Birmingham, Alabama +38 locations
Conditions: Extensive-stage Small Cell Lung Cancer
157 - 168 of 336
